Search

Revati Shreeniwas

from Palo Alto, CA
Age ~64
Get Report
Also known as:
Revati C Srinagesh, Revati S Srinagesh, Ravati Shreeniwas, Shreeniwas Srinagesh, Shreeniwas Revati, Revati S, Revita I
Phone and address:
819 Sutter Ave, Palo Alto, CA 94303
(650) 856-2918
Related to:
Mark A Pettway, 70Darwin T PettawayJoseph Bell, 64Lucinda Franklin, 68Lucinda P Cox, 77
Connected to:
Satya S Shreenivas, 43Chanda Shreeve, 53Cheryl M Shreeves, 67Lance Shreeve, 32Leah D Shreeve, 54Mathew W Shreeve, 43Melanie A Shreeve, 55Shelly Shreeve, 60Terry D Shreeve, 70Claudia K Shreffler, 73

Revati Shreeniwas Phones & Addresses

  • 819 Sutter Ave, Palo Alto, CA 94303 (650) 856-2918
  • New York, NY
  • Teaneck, NJ
  • Westphalia, MO
  • Worcester, MA

Work

Company: Stanford Hospital and Clinics Address: 300 Pasteur Drive, Stanford, CA 94305

Education

School / High School: University of Pune / Armed Forces Medical College

Skills

Biotechnology • Pharmaceuticals • Clinical Trials • Oncology • Clinical • Clinical Research • Pharmaceutical Industry • Pharmacovigilance • Infectious Diseases • Gastroenterology • Clinical Development • Healthcare • Gcp • Lifesciences • Immunology • Medicine • Ind • Therapeutic Areas • Internal Medicine • Neurology • Regulatory Submissions • Medical Devices • Commercialization • Clinical Operations • Ophthalmology • Drug Development • Cardiology • Fda • Drug Discovery • Life Sciences

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Critical Care Medicine, 1995

Industries

Biotechnology

Specialities

Critical Care Medicine • Pulmonology

Professional Records

Medicine Doctors

Revati Shreeniwas Photo 1

Dr. Revati Shreeniwas, Palo Alto CA - MD (Doctor of Medicine)

View page
Specialties:
Critical Care Medicine
Pulmonology
Address:
819 Sutter Ave, Palo Alto, CA 94303
(650) 723-4000 (Phone), (650) 723-4000 (Fax)

300 Pasteur Dr, Stanford, CA 94305
(650) 498-7103 (Phone)
Certifications:
Critical Care Medicine, 1995
Internal Medicine, 1989
Pulmonary Disease, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
819 Sutter Ave, Palo Alto, CA 94303

300 Pasteur Dr, Stanford, CA 94305

Stanford Hospital and Clinics
300 Pasteur Drive, Stanford, CA 94305
Education:
Medical School
University of Pune / Armed Forces Medical College
Medical School
Worcester City Hosp
Medical School
Columbia Coll P&S

License Records

Revati Shreeniwas

Address:
Palo Alto, CA
License #:
25MA05448800 - Expired
Category:
Medical Examiners
Issued Date:
Dec 3, 1990
Expiration Date:
Jun 30, 1997
Type:
Medical Doctor

Revati Shreeniwas

Address:
Palo Alto, CA
License #:
25MA05448800 - Expired
Category:
Medical Examiners
Issued Date:
Dec 3, 1990
Expiration Date:
Jun 30, 1997
Type:
Medical Doctor

Resumes

Resumes

Revati Shreeniwas Photo 2

Revati Shreeniwas

View page
Location:
Palo Alto, CA
Industry:
Biotechnology
Skills:
Biotechnology
Pharmaceuticals
Clinical Trials
Oncology
Clinical
Clinical Research
Pharmaceutical Industry
Pharmacovigilance
Infectious Diseases
Gastroenterology
Clinical Development
Healthcare
Gcp
Lifesciences
Immunology
Medicine
Ind
Therapeutic Areas
Internal Medicine
Neurology
Regulatory Submissions
Medical Devices
Commercialization
Clinical Operations
Ophthalmology
Drug Development
Cardiology
Fda
Drug Discovery
Life Sciences

Business Records

Name / Title
Company / Classification
Phones & Addresses
Revati Shreeniwas
President
REVATI, INC., A MEDICAL CORPORATION
819 Sutter Ave, Palo Alto, CA 94303
Revati Shreeniwas
CTO
Alvine
Research and Development in the Social Sciences and Humaniti
75 Shoreway Rd, San Carlos, CA 94070
(650) 632-1645
Revati Shreeniwas
Revati Shreeniwas MD
Internist
425 W 59 St, New York, NY 10019
(212) 523-7090

Publications

Us Patents

Methods Of Use For Monomethyl Fumarate And Prodrugs Thereof

View page
US Patent:
20140057918, Feb 27, 2014
Filed:
Aug 22, 2013
Appl. No.:
13/973820
Inventors:
Peter A. Virsik - Portola Valley CA, US
Mark A. Gallop - Palo Alto CA, US
Kenneth C. Cundy - Redwood City CA, US
Dmitri V. Lissin - Santa Clara CA, US
Revati Shreeniwas - Palo Alto CA, US
Assignee:
XenoPort, Inc. - Santa Clara CA
International Classification:
C07C 69/60
C07D 265/30
US Classification:
5142392, 514547
Abstract:
Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.

Methods And Compositions For Treatment Of Pulmonary Hypertension And Other Lung Disorders

View page
US Patent:
20220347183, Nov 3, 2022
Filed:
Jun 29, 2022
Appl. No.:
17/853005
Inventors:
- Albuquerque NM, US
Alain Romero - Brisbane CA, US
Hugh Smyth - West Lake Hills TX, US
Robert Curtis - Santa Fe NM, US
Adaani Frost - Houston TX, US
Zhen Xu - Rockville MD, US
Revati Shreeniwas - Palo Alto CA, US
Martin Donovan - Austin TX, US
Assignee:
Respira Therapeutics, Inc. - Albuquerque NM
International Classification:
A61K 31/53
A61P 9/12
A61K 9/00
A61K 9/16
A61K 31/192
A61K 31/506
Abstract:
Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Methods And Compositions For Treatment Of Pulmonary Hypertension And Other Lung Disorders

View page
US Patent:
20210205318, Jul 8, 2021
Filed:
Jan 11, 2021
Appl. No.:
17/146173
Inventors:
- Albuquerque MN, US
Alain ROMERO - Brisbane CA, US
Hugh SMYTH - West Lake Hills TX, US
Robert CURTIS - Santa Fe NM, US
Adaani FROST - Houston TX, US
Zhen XU - Rockville MD, US
Revati SHREENIWAS - Palo Alto CA, US
Martin DONOVAN - Austin TX, US
International Classification:
A61K 31/53
A61P 9/12
A61K 9/00
A61K 9/16
A61K 31/192
A61K 31/506
Abstract:
Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Methods And Compositions For Treatment Of Pulmonary Hypertension And Other Lung Disorders

View page
US Patent:
20200093830, Mar 26, 2020
Filed:
Dec 14, 2017
Appl. No.:
16/469524
Inventors:
- Albuquerque NM, US
Alain ROMERO - Brisbane CA, US
Hugh SMYTH - West Lake Hills TX, US
Robert CURTIS - Santa Fe NM, US
Adaani FROST - Houston TX, US
Zhen XU - Rockville MD, US
Revati SHREENIWAS - Palo Alto CA, US
Martin DONOVAN - Austin TX, US
International Classification:
A61K 31/53
A61K 9/00
A61K 31/192
A61K 31/506
A61K 9/16
A61P 9/12
Abstract:
Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Pde5 Inhibitor Powder Formulations And Methods Relating Thereto

View page
US Patent:
20160317542, Nov 3, 2016
Filed:
Dec 9, 2014
Appl. No.:
15/102957
Inventors:
- Albuquerque NM, US
Hugh Smyth - West Lake Hills TX, US
Aileen Gibbons - New York NY, US
Revati Shreeniwas - Palo Alto CA, US
Pravin Soni - Sunnyvale CA, US
Dan Deaton - Apex NC, US
James Hannon - Albuquerque NM, US
Stephen Lermer - Austin TX, US
Robert Curtis - Santa Fe NM, US
Assignee:
Respira Therapeutics, Inc. - Albuquerque NM
International Classification:
A61K 31/53
A61K 47/26
A61M 15/00
A61K 9/00
Abstract:
Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
Control profile
Revati Shreeniwas from Palo Alto, CA, age ~64 Get Report